The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence., Bizz ...
On March 19, Barclays raised its price recommendation on Johnson & Johnson (NYSE:JNJ) to $234 from $217. It kept an Equal ...
As Dream Finders Homes Inc.’s stock fell to three-year lows recently, Forbes magazine’s annual billionaires list showed a ...
Monte Rosa (GLUE) shares rise as it teams with Johnson & Johnson to test MRT-2359 + ERLEADA in mCRPC AR mutations in a Phase ...
Johnson & Johnson’s TECNIS Odyssey IOL launched in India, offering a full visual range and high contrast to reduce spectacle dependency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results